Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $155.
A big investment bank says Abivax looks like a good company and sets a target price of $155. When experts start paying attention to a stock, it means they think the business might be worth watching more carefully.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.